AstraZeneca PLC (AZN) Operating Cash Flow CAGR:9.33%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over longer horizons, AstraZeneca PLC's Operating Cash Flow CAGR averages 13.80% over 3 years and 16.76% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash AstraZeneca PLC generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
AZN Operating Cash Flow CAGR Chart
AstraZeneca PLC (AZN)
AZN Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
AZN Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $11.86B | $14.57B | +$2.71B | +22.88% | +22.88% |
| 2024 | $10.35B | $11.86B | +$1.52B | +14.65% | +14.65% |
| 2023 | $9.81B | $10.35B | +$537.00M | +5.48% | +5.48% |
| 2022 | $5.96B | $9.81B | +$3.85B | +64.48% | +64.48% |
| 2021 | $4.80B | $5.96B | +$1.16B | +24.26% | +24.26% |
| 2020 | $2.97B | $4.80B | +$1.83B | +61.64% | +61.64% |
| 2019 | $2.62B | $2.97B | +$351.00M | +13.41% | +13.41% |
| 2018 | $3.58B | $2.62B | $-960.00M | -26.83% | -26.83% |
| 2017 | $4.14B | $3.58B | $-567.00M | -13.68% | -13.68% |
| 2016 | $3.32B | $4.14B | +$821.00M | +24.70% | +24.70% |
| 2015 | $7.06B | $3.32B | $-3.73B | -52.90% | -52.90% |
| 2014 | $7.40B | $7.06B | $-342.00M | -4.62% | -4.62% |
| 2013 | $6.95B | $7.40B | +$452.00M | +6.51% | +6.51% |
| 2012 | $7.82B | $6.95B | $-873.00M | -11.16% | -11.16% |
| 2011 | $10.68B | $7.82B | $-2.86B | -26.77% | -26.77% |
| 2010 | $11.74B | $10.68B | $-1.06B | -9.02% | -9.02% |
| 2009 | $8.74B | $11.74B | +$3.00B | +34.28% | +34.28% |
| 2008 | $7.51B | $8.74B | +$1.23B | +16.40% | +16.40% |
| 2007 | $7.69B | $7.51B | $-183.00M | -2.38% | -2.38% |
| 2006 | $6.74B | $7.69B | +$950.00M | +14.09% | +14.09% |
| 2005 | $4.87B | $6.74B | +$1.87B | +38.37% | +38.37% |
| 2004 | $3.42B | $4.87B | +$1.46B | +42.65% | +42.65% |
| 2003 | $4.83B | $3.42B | $-1.42B | -29.32% | -29.32% |
| 2002 | $2.71B | $4.83B | +$2.13B | +78.57% | +78.57% |
| 2001 | $2.34B | $2.71B | +$370.51M | +15.86% | +15.86% |
| 2000 | $908.55M | $2.34B | +$1.43B | +157.11% | +157.11% |
| 1999 | $879.74M | $908.55M | +$28.81M | +3.28% | +3.28% |
| 1998 | $747.21M | $879.74M | +$132.53M | +17.74% | +17.74% |
| 1997 | $787.75M | $747.21M | $-40.55M | -5.15% | -5.15% |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $3.36B | +38.2% | -9.5% |
| Q4 2025 | $2.43B | -52.7% | -16.4% |
| Q3 2025 | $5.13B | +51.6% | +51.8% |
| Q2 2025 | $3.39B | -8.8% | +9.8% |
| Q1 2025 | $3.71B | +27.7% | +49.4% |
| Q4 2024 | $2.91B | -14.1% | +22.1% |
| Q3 2024 | $3.38B | +9.7% | +8.6% |
| Q2 2024 | $3.08B | +24.1% | +79.6% |
| Q1 2024 | $2.49B | +4.5% | -20.7% |
| Q4 2023 | $2.38B | -23.6% | -0.8% |
| Q3 2023 | $3.11B | +81.3% | +6.3% |
| Q2 2023 | $1.72B | -45.2% | +37.7% |
| Q1 2023 | $3.13B | +30.7% | -3.1% |
| Q4 2022 | $2.40B | -18.2% | +69.1% |
| Q3 2022 | $2.93B | +134.8% | +70.4% |
| Q2 2022 | $1.25B | -61.4% | +39.9% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot